Prelude Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Prelude Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-21,000	Closed	-$2.35M	–	2291
2021 Q4	$2.35M	Buy	+21,000	New	+$2.53M	0.06%	264
2021 Q3	–	Sell	-1,500	Closed	-$203K	–	2061
2021 Q2	$203K	Buy	+1,500	New	+$197K	0.01%	1374
2021 Q1	–	Sell	-13,200	Closed	-$1.86M	–	1857
2020 Q4	$1.86M	Buy	13,200 +11,900	+915%	+$1.52M	0.05%	314
2020 Q3	$145K	Sell	1,300 -2,300	-64%	-$258K	0.01%	782
2020 Q2	$403K	Buy	+3,600	New	+$355K	0.02%	532
2020 Q1	–	Sell	-18,300	Closed	-$455K	–	2106
2019 Q4	$455K	Buy	+18,300	New	+$1.58M	0.02%	587
2019 Q2	–	Sell	-22,100	Closed	-$691K	–	2203
2019 Q1	$691K	Buy	22,100 +4,000	+22%	+$340K	0.04%	417
2018 Q4	$498K	Sell	18,100 -15,400	-46%	-$1.24M	0.03%	470
2018 Q3	$2.41M	Buy	+33,500	New	+$3.25M	0.14%	146
2018 Q2	–	Sell	-21,200	Closed	-$1.86M	–	1977
2018 Q1	$1.86M	Buy	+21,200	New	+$1.94M	0.14%	134
2017 Q4	–	Sell	-300	Closed	-$26K	–	1758
2017 Q3	$26K	Sell	300 -111,300	-100%	-$8.92M	﹤0.01%	1262
2017 Q2	$4.55M	Buy	+111,600	New	+$7.92M	0.43%	51

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Prelude Capital Management's XBI Position: Q3 2025 in Review

Prelude Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 15,000 shares — an estimated $1.24M sold.

Prelude Capital Management first reported a position in XBI in Q1 2015 and held it in 7 quarters. The position peaked at $1.33M in Q2 2021. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Prelude Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 15,000 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $1.24M.
Prelude Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and held it in 7 quarters.
Prelude Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.33M in Q2 2021.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.